ERBB2 and neoplasm: The table summarizes polymer/tumor-specific patterns and implicated agents (e.g., doxorubicin, taxanes, HER2/EGFR inhibitors), emphasizing the need to measure MP exposure in preclinical efficacy studies (Table 3).